Compare Marathon Petroleum Corp (MPC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Neurocrine Biosciences Inc — how do they compare? Marathon Petroleum Corp trades at $461.58 (market cap $130.12B), while Neurocrine Biosciences Inc trades at $142.61 (market cap $14.36B). The key difference: Marathon Petroleum Corp is far larger — about 9.1× Neurocrine Biosciences Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MPC | NBIX | |
|---|---|---|
Market Cap | $130.12B | $14.36B |
Volume | 2,749,647 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $463.34 | $185.50 |
52-Week Low | $162.63 | $123.10 |
Typical Hold Time | 54 Days | 23 Days |
Enterprise Value | $156.64B | $14.37B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $461.79, up 4.42% today, showing strong momentum with three consecutive earnings beats. Technical indicators signal bullish momentum with the stock trading near resistance at $463. Fundamentally, the company maintains solid profitability with 5.57% net margin and 47.9% ROE, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Analyst consensus remains strongly bullish with 25 buy ratings and a $420.30 price target.
MPC presents a compelling value opportunity with attractive valuation multiples (P/E 16.07, P/S 0.9) and strong earnings momentum. Key risks include potential diesel export restrictions, declining revenue trends, and elevated debt levels. The stock's current price above consensus target suggests near-term caution despite positive technical and fundamental momentum.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
